Introduction: To investigate the safety and efficacy of using different anticoagulants after left atrial appendage closure with Watchman device.

Methods: Patients with successfully Watchman device implanted were included. All the patients were received anticoagulants within 45 days after the procedure (including warfarin, rivaroxaban and dabigatran).

Result: A total of 285 patients were consecutively selected. The study population was divided into 3 groups: warfarin group (n=80), dabigatran group (n=114), and rivaroxaban group (n=91). The peri-procedure complications and device-related thrombus (2.5% vs 0.8% vs 1.1%, P=0.803) were comparable between groups.

Conclusion: The safety and efficacy of dabigatran and rivaroxaban was comparable with warfarin within 45 days after Watchman device implantation.